How AI is Shaping the Future of Drug Discovery and Chemistry

Artificial Intelligence (AI) is already having a major impact on the pharmaceutical industry, and it has the potential to revolutionize medicinal chemistry and unlock new possibilities in drug discovery. 

To learn more, we spoke to Dr. Kevin Hunt, Chief Scientific Officer at Vanqua Bio and CEO at Genuiti Therapeutics, who brings decades of experience to the intersection of drug development and cutting-edge technologies like AI. With over 50 patents and publications and a track record of discovering clinical candidates for life-threatening diseases, Dr. Hunt has witnessed firsthand how AI is reshaping the research landscape

“I think within the next five years, AI will be on the desk of most medicinal chemists, and not just as a tool, but as an essential desktop app,” he said, highlighting the growing role AI plays in the daily workflows of researchers.

What is Artificial Intelligence in Drug Discovery?

Artificial intelligence in drug discovery—also known as AI-powered drug development or AI-assisted drug design—refers to the use of machine learning, deep learning, and data analysis technologies to accelerate and improve the pharmaceutical development process. AI systems can analyze vast datasets, identify patterns, and predict outcomes that would be impossible for human researchers to process manually.

These technologies enable pharmaceutical researchers to process millions of data points from clinical trials, genetic databases, and published literature simultaneously, identifying potential drug targets and therapeutic approaches that might take human teams years to discover through traditional methods.

This matters because AI can analyze millions of molecular combinations in hours, cutting drug discovery timelines from years to months and potentially saving billions in R&D costs

How Has AI in Drug Discovery Evolved Over Time?

AI's relationship with chemistry and drug discovery has evolved through several distinct phases over six decades:

• 1960s-1980s: Early expert systems like DENDRAL and MYCIN automated molecular identification and medical diagnosis
• 1980s-2000s: Statistical QSAR models and machine learning techniques like support vector machines improved drug prediction
• 2010s-Present: Deep learning and neural networks revolutionized molecular structure analysis and drug discovery

Understanding AI’s evolution helps researchers choose the right tools for today’s challenges and predict how emerging technologies could reshape future drug pipelines.

Let’s take a closer look at each of these periods: 

• The Foundation Years (1960s-1980s)
  The connection began in the 1960s with the DENDRAL (DENDRitic ALgorithm) project at Stanford University, which automated the identification of unknown organic molecules by analyzing mass spectra and chemical data. This early system proved that computers could effectively manage tasks requiring specialized scientific expertise.
  
  In the 1970s-1980s, expert systems like MYCIN emerged, extending AI's reach into medical applications and drug design. MYCIN, also developed at Stanford, was used for diagnosing blood infections and recommending antibiotics.
• The Statistical Modeling Era (1980s-2000s)
  During the 1980s-1990s, Quantitative Structure-Activity Relationship (QSAR) models used statistical methods to correlate chemical structures with their biological effects, greatly accelerating the drug discovery process.
  
  From the late 1990s through the 2000s, machine learning techniques like support vector machines and random forests began to be applied to chemical problems, offering improved predictive power over traditional statistical methods.
• The Modern AI Revolution (2010s-Present)
  The 2010s-present era has seen deep learning and neural networks revolutionize chemical predictions, offering unprecedented insights into molecular structures and interactions.
  
  "The newer AI models allow you to do great things with your PC, offering more opportunities with much less heavy lifting,” Dr. Hunt explained. This democratization of tech has lowered entry barriers for smaller research teams, potentially accelerating drug discovery.

How Is AI Used in Drug Discovery?

AI is currently transforming pharmaceutical research through four key applications:

• Patient population analysis: Identifying specific groups most likely to benefit from particular treatments
• Disease pathway mapping: Understanding disease mechanisms faster through data analysis
• Bias reduction: Providing unbiased analysis of research data and drug targets
• Personalized Medicine: Matching treatments to individual patient genetic profiles

These applications matter because they target the biggest bottlenecks in pharma: patient selection, disease understanding, bias reduction, and precision medicine.

Let’s explore these four applications further:  

• Analyzing Patient Populations for Targeted Therapies
  “AI is great for sifting through publications, finding connections in data from patents and research, and bringing together pathways for personalized medicine and genetics,” Dr. Hunt explained. By identifying patterns that human researchers might overlook, AI can help pinpoint specific patient groups most likely to benefit from particular treatments.
  
  This capability is particularly valuable for developing precision medicines that work for specific genetic profiles or disease subtypes, rather than broad population approaches.
  
  
• Mapping Disease Pathways and Mechanisms
  AI's data processing capabilities extend to identifying and mapping disease pathways. By analyzing vast datasets of genetic information, clinical trials, and research, AI helps researchers understand disease mechanisms more quickly and thoroughly.
  
  This accelerated understanding can lead to more targeted drug development, potentially reducing time and costs for bringing new treatments to market.
  
  
• Reducing Human Bias in Research Analysis
  “AI does that better than humans do, in my opinion," Dr. Hunt said, "if you feed it the right data set.” 
  
  This unbiased approach can uncover important connections or potential treatments that might be overlooked due to preconceived notions.
  
  Human researchers naturally bring their own experiences and assumptions to data interpretation. AI systems can process the same information without these cognitive biases, potentially revealing unexpected drug targets or therapeutic approaches.
  
  
• Accelerating Personalized Medicine Development
  “That's where it's at for me,” Dr. Hunt said. “I think AI's capacity to analyze and connect data sets and published information and disease pathology from diverse sources is incredibly valuable in this context.”
  
  By analyzing individual patient data alongside vast genetic and treatment outcome databases, AI can identify the most effective treatments for specific patient profiles, significantly improving outcomes and reducing trial-and-error approaches. This shift marks the next phase of artificial intelligence in pharma R&D, where AI-driven drug innovation is unlocking precision treatments.
  
  

What Are the Biggest Challenges for AI in Pharma R&D?

Despite its potential, AI in drug discovery faces several significant obstacles:

• 3D molecular complexity: Difficulty predicting three-dimensional drug-protein interactions
• Poor data quality: Inconsistent reporting standards and incomplete datasets
• Data advantage gap: Large pharma's competitive advantage through decades of proprietary data
• Intellectual property issues: Complex questions about AI-discovered drug ownership
• Workforce disruption: Need to balance AI capabilities with human expertise

   

Let’s take a closer look at these challenges: 

Understanding Three-Dimensional Molecular Interactions
“Making a drug is all about three-dimensionality,” Dr. Hunt noted, highlighting the difficulty in accurately predicting molecular interactions in 3D space.

AI models, especially those based on 2D molecular representations, often struggle to capture this complexity, leading to predictions that may not translate well to real-world drug behavior. Drug molecules must fit precisely into target proteins, and these interactions happen in complex three-dimensional space.

Overcoming Poor Data Quality Issues
“The quality of the data coming in is often poor or not well reported,” Dr. Hunt pointed out. This can include inconsistent reporting standards, incomplete datasets, and errors in published literature, which can severely hamper the predictive power of AI models.

The pharmaceutical industry has decades of research data, but much of it was collected before modern data standards existed. Cleaning and standardizing this information for AI use remains a major challenge.

Addressing the Data Advantage Gap
“Large pharmaceutical companies have decades of data from previous drug development efforts to feed the beast and train robust AI models,” Dr. Hunt explained. This data advantage could widen the gap between big pharma and smaller players, potentially impacting industry competition and innovation.

Smaller biotech companies often lack the extensive historical datasets needed to train sophisticated AI models, creating potential competitive disadvantages.

Navigating Intellectual Property Concerns
“If you don't have your IP, you don't have anything in terms of drug discovery and development,” Dr. Hunt said. 

The use of AI in drug discovery raises complex questions about IP rights. If an AI system identifies a novel drug candidate, who owns the rights to that discovery? How can companies protect their proprietary data when using third-party AI tools?

How Can Companies Use or Access AI for Drug Discovery?

Pharmaceutical companies can access AI capabilities for drug discovery through several approaches: building internal AI teams, partnering with technology companies, or working with specialized service providers. Contract Development and Manufacturing Organizations (CDMOs) have emerged as a particularly effective option because they combine AI technologies with deep pharmaceutical expertise and regulatory knowledge.

Solving Complex Chemistry Problems
“Quality CDMOs like GL CHEMTEC don't get the easy problems,” Dr. Hunt said. “They solve problems other people haven't thought of, things like, 'What's a polymer we should consider that we haven't?'”

By combining extensive expertise with cutting-edge AI technologies, specialized CDMOs can address complex pharmaceutical challenges that might be beyond the scope or capabilities of individual pharmaceutical companies.

Bridging the Expertise Gap for Smaller Companies
Partnering with tech-savvy and AI-powered CDMOs can help bridge the gap between novice researchers and seasoned experts by providing data-driven insights and suggestions. This democratization of expertise allows smaller biotech companies and startups to tackle complex problems that might have previously been out of reach.

Facilitating Collaborative AI Development
“CDMOs can play a crucial role in bringing together dozens of companies to pool our data for training AI systems,” Dr. Hunt explained. “This collaborative approach allows us to create more robust prediction models based on larger, more diverse datasets.”

CDMOs are well-positioned to facilitate collaborative efforts in AI and data sharing. By acting as neutral third parties, they can aggregate data from multiple sources, ensuring that AI models are trained on diverse and comprehensive datasets.

Balancing AI Technology with Human Intelligence
“When I reach out to a partner, I'm looking for someone who understands where I need help and can key in on the problem,” Dr. Hunt said. “If they have AI helping them, that's fantastic. But with companies like GL CHEMTEC, you're also getting real-world problem-solving experience. Artificial intelligence is great, but combining it with real intelligence is even better.”

The most effective approach combines AI's computational power with human expertise in chemistry, biology, and drug development. Leading CDMOs provide both cutting-edge technology and deep industry experience.

What Should You Look for in an AI Drug Development Partner?

Companies can access AI for drug discovery through several partnership models:

• Technology vendors: Pure AI software and platforms
• Consulting firms: Strategic AI implementation guidance
• Specialized CDMOs: Combined AI technology with pharmaceutical manufacturing expertise

For companies seeking integrated AI and development services, CDMOs offer unique advantages. 

When selecting a CDMO partner that leverages AI technology, evaluate these key factors:

Technical Expertise and Innovation
Look for CDMOs that demonstrate both AI capabilities and deep pharmaceutical expertise. The ideal partner should have scientists who understand both the computational and practical aspects of drug development.

Data Security and Intellectual Property Protection
Given the sensitive nature of pharmaceutical data, choose partners with robust data security measures and clear intellectual property protections. This is especially important when AI systems process proprietary compound data.

Collaborative Approach to Problem-Solving
The best AI-enabled CDMOs work as true partners, combining their technological capabilities with your team's expertise to solve complex challenges collaboratively rather than simply executing predetermined tasks.

Proven Track Record in Complex Chemistry
Evaluate potential partners based on their ability to handle sophisticated chemistry challenges, not just their technological capabilities. The combination of AI tools and experienced chemists produces the best results.

GLC: Your Trusted CRO/CDMO Partner

GL CHEMTEC is passionate about your success and committed to solving your most complex chemistry challenges. We offer fast, flexible, cutting-edge solutions to take your medicinal chemistry and early-stage small-molecule routes to the next level. Our commitment to a collaborative partnership means we scale and adapt precisely to meet your evolving needs.

GL CHEMTEC provides:

• A secure North American alternative to overseas providers, offering R&D labs, Kilo labs and scale-up facilities in the Greater Toronto area
• Expert custom formulation development for pharmaceutical and medical device applications
• A local partner who will ensure secure shipping, real-time communication and the highest levels of IP protection for your early stage work
• A highly customer-centric culture with a 20+ track record of success
• ISO 9001:2015 and ISO 13485:2016 certifications
• A GMP Compliant Cleanroom with GMP Reactor Suites